News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oscient Pharmaceuticals Corporation (OSCI) Acquires Expanded Worldwide Rights To Lead Clinical Candidate Ramoplanin



2/8/2006 10:41:13 AM

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 8, 2006--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) and Pfizer Inc subsidiary Vicuron Pharmaceuticals Inc., have restructured the business relationship for Oscient's lead clinical candidate, Ramoplanin, currently in development for the potential treatment of Clostridium difficile-associated disease (CDAD). As part of the new arrangement, Oscient, which previously licensed Ramoplanin from Vicuron for the U.S. and Canada only, acquired worldwide rights and assumes full control of Ramoplanin manufacturing, development and commercialization on a global basis. Oscient recently agreed on a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration for the Phase III program of Ramoplanin.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES